撤稿:PD-L1和PD-1在前列腺癌中的表达及其临床意义
RETRACTED:Expressions and Clinical Significance of PD-L1 and PD-1 in Prostate Cancer

作者: 延敏博 , 练文飞 , 黄书畅 , 程文杰 , 戴英波 :中山大学附属第五医院泌尿外科,广东 珠海; 路 静 :中山大学附属第五医院消化内科,广东 珠海;

关键词: 前列腺癌PD-L1PD-1Prostate Cancer PD-L1 PD-1

摘要: 撤稿声明:“PD-L1和PD-1在前列腺癌中的表达及其临床意义”一文刊登在2019年6月出版的《亚洲外科手术病例研究》2019年第8卷第2期第9-14页上。因该论文作者在统计分析的时候,夸大了文章中的病例数量,实际检测例数并未达到文章中的数量,现主动要求撤稿。编委会现决定撤除此稿件,保留原出版出处:延敏博, 练文飞, 黄书畅, 程文杰, 路静, 戴英波. PD-L1和PD-1在前列腺癌中的表达及其临床意义[J]. 亚洲外科手术病例研究, 2019, 8(2): 9-14. https://doi.org/10.12677/ACRS.2019.82002

Abstract:

文章引用: 延敏博 , 练文飞 , 黄书畅 , 程文杰 , 路 静 , 戴英波 (2019) 撤稿:PD-L1和PD-1在前列腺癌中的表达及其临床意义。 亚洲外科手术病例研究, 8, 9-14. doi: 10.12677/ACRS.2019.82002

参考文献

[1] Modena, A., Ciccarese, C., Iacovelli, R., et al. (2016) Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncology Reviews, 10, 293.
https://doi.org/10.4081/oncol.2016.293

[2] Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H. and Riley, J.L. (2004) SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 Upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology, 173, 945-954.
https://doi.org/10.4049/jimmunol.173.2.945

[3] Fife, B.T., Guleria, I., Gubbels Bupp, M., et al. (2006) Insulini-Induced Remission in New-Onset NOD Mice Is Maintained by the PD-1-PD-L1 Pathway. The Journal of Experimental Medicine, 203, 2737-2747.
https://doi.org/10.1084/jem.20061577

[4] Tsushima, F., Yao, S., Shin, T., et al. (2007) Interaction between B7-H1 and PD-1 Determines Initiation and Reversal of T-Cell Anergy. Blood, 110, 180-185.
https://doi.org/10.1182/blood-2006-11-060087

[5] Mountzios, G., Linardou, H. and Kosmidis, P. (2016) Immunotherapy in Non-Small Cell Lung Cancer: The Clinical impact of Immune Response and Targeting. Annals of Translational Medicine, 4, 268.
https://doi.org/10.21037/atm.2016.06.24

[6] Albertsen, P. (2008) Predicting Survival for Men with Clinically Localized Prostate Cancer: What Do We Need in Contemporary Practice? Cancer, 112, 1-3.
https://doi.org/10.1002/cncr.23107

[7] So, A., Gleave, M., Hurtado-Col, A. and Nelson, C. (2005) Mechanisms of the Development of Androgen Independence in Prostate Cancer. World Journal of Urology, 23, 1-9.
https://doi.org/10.1007/s00345-004-0473-1

[8] Gajewski, T.F., Meng, Y. and Harlin, H. (2006) Immune Suppression in the Tumor Microenvironment. Journal of Immunotherapy, 29, 233-240.
https://doi.org/10.1097/01.cji.0000199193.29048.56

[9] Dong, H., Strome, S.E., Salomao, D.R., et al. (2002) Tu-mor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nature Medicine, 8, 793-800.
https://doi.org/10.1038/nm730

[10] Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Tolerance and Immunity. Annual Review of Immunology, 26, 677-704.
https://doi.org/10.1146/annurev.immunol.26.021607.090331

[11] Wang, L., Ma, Q., Chen, X., et al. (2010) Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma. World Journal of Surgery, 34, 1059-1065.
https://doi.org/10.1007/s00268-010-0448-x

[12] Hasan, A., Ghebeh, H., Lehe, C., Ahmad, R. and Dermime, S. (2011) Thera-peutic Targeting of B7-H1 in Breast Cancer. Expert Opinion on Therapeutic Targets, 15, 1211-1225.
https://doi.org/10.1517/14728222.2011.613826

[13] Karim, R., Jordanova, E.S., Piersma, S.J., et al. (2009) Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. Clinical Cancer Research, 15, 6341-6347.
https://doi.org/10.1158/1078-0432.CCR-09-1652

[14] Hsu, M.C., Hsiao, J.R., Chang, K.C., et al. (2010) Increase of Programmed Death-1-Expressing Intratumoral CD8 T Cells Predicts a Poor Prognosis for Nasopharyngeal Carcinoma. Modern Pathology, 23, 1393-1403.
https://doi.org/10.1038/modpathol.2010.130

[15] Loos, M., Langer, R., Schuster, T., et al. (2011) Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma. The Annals of Thoracic Surgery, 91, 1025-1031.
https://doi.org/10.1016/j.athoracsur.2010.12.041

[16] Seo, S.K., Seo, H.M., Jeon, H.Y., et al. (2006) Co-Inhibitory Role of T Cell Associated B7-H1 and B7-DC in the T-Cell Immune Response. Immunology Letters, 102, 222-228.
https://doi.org/10.1016/j.imlet.2005.09.007

[17] Hinrichs, C.S., Spolski, R., Paulos, C.M., et al. (2008) IL-2 and IL-24 Con-fer-Opposing Differentiation Programs to CD8+ T Cells for Adoptive Immunotherapy. Blood, 111, 5326-5333.
https://doi.org/10.1182/blood-2007-09-113050

[18] 王永华. 共刺激分子B7-H1和Fasl在膀胱移行细胞癌免疫逃逸中的机制研究及临床意义[J]. 临床泌尿外科杂志, 2008, 23(9): 684-486.

[19] Yang, S., Zhang, Q., Liu, S., et al. (2016) PD-1, PD-L1 and PD-L2 Expression in Mouse Prostate Cancer. American Journal of Clinical and Experimental Urology, 4, 1-8.

[20] Graff, J.N., Alumkal, J.J., Drake, C.G., et al. (2016) Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer. Oncotarget, 7, 52810-52817.
https://doi.org/10.18632/oncotarget.10547

分享
Top